Stocktoria
Kiniksa Pharmaceuticals International, plc KNSA
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2018-05-24
Kiniksa Pharmaceuticals International, plc financials (annual)
Bars are annual figures from 2017 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $677.6M | $423.2M | $270.3M | $220.2M | $38.5M | — | — | — | — |
| R&D expense | $96.9M | $111.6M | $76.1M | $65.5M | $99.3M | $112.0M | $135.0M | $86.6M | $56.4M |
| SG&A expense | $196.3M | $168.0M | $129.4M | $98.0M | $85.9M | $45.3M | $35.0M | — | — |
| Operating income | $77.2M | -$45.6M | -$25.2M | $9.8M | -$156.6M | -$157.4M | -$170.0M | -$108.2M | -$65.4M |
| Income tax | $29.9M | $7.0M | -$30.7M | -$172.3M | $1.4M | $5.2M | -$2.0M | -$214,000 | $2,000 |
| Net income | $59.0M | -$43.2M | $14.1M | $183.4M | -$157.9M | -$161.4M | -$161.9M | -$103.2M | -$64.9M |
| EPS (diluted) | $0.75 | $-0.60 | $0.20 | $2.60 | $-2.30 | $-2.61 | $-2.99 | — | — |
| Operating cash flow | $138.0M | $25.7M | $13.3M | $5.8M | -$126.3M | -$136.5M | -$158.4M | -$81.0M | -$50.2M |
| Free cash flow | $136.4M | $25.4M | $13.2M | $5.7M | -$126.7M | -$136.8M | -$161.6M | -$86.3M | -$50.3M |
| Cash & equivalents | $165.6M | $183.6M | $108.0M | $122.7M | $122.5M | $114.0M | $46.9M | $72.0M | $45.6M |
| Inventory | $54.9M | $26.4M | $31.1M | $21.6M | $3.7M | $0 | — | — | — |
| Total assets | $763.6M | $580.6M | $526.3M | $459.7M | $232.8M | $349.5M | $254.5M | $322.0M | $47.5M |
| Total liabilities | $196.0M | $142.1M | $87.5M | $63.5M | $47.8M | $37.5M | $29.1M | $42.7M | $17.4M |
| Shareholders' equity | $567.6M | $438.4M | $438.8M | $396.1M | $185.0M | $311.9M | $225.4M | $279.3M | -$89.7M |
Growth · year-over-year · Revenue CAGR 104.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +60.1% | +56.6% | +22.7% | +471.2% | — | — | — | — | — |
| Net income growth | — | -406.7% | -92.3% | — | — | — | — | — | — |
| EPS growth | — | -400.0% | -92.3% | — | — | — | — | — | — |
| Free cash flow growth | +436.8% | +92.9% | +131.0% | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.